Literature DB >> 28336182

Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role?

Chunlan Zhang1, Xufei Huang1, Jian Li2.   

Abstract

Amyloid light-chain (AL) amyloidosis is a plasma-cell dyscrasia, as well as the most common type of systematic amyloidosis. Pathogenic plasma cells that have distinct cytogenetic and molecular properties secrete an excess amount of amyloidogenic light chains. Assisted by post-translational modifications, matrix components, and other environmental factors, these light chains undergo a conformational change that triggers the formation of amyloid fibrils that overrides the extracellular protein quality control system. Moreover, the amyloidogenic light-chain itself is cytotoxic. As a consequence, organ dysfunction is caused by both organ architecture disruption and the direct cytotoxic effect of amyloidogenic light chains. Here, we reviewed the molecular mechanisms underlying this sequence of events that ultimately leads to AL amyloidosis and also discuss current in vitro and in vivo models, as well as relevant novel therapeutic approaches.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cytotoxicity; Fibrillogenesis; Light-chain amyloidosis; Molecular mechanism; Pathogenesis

Mesh:

Substances:

Year:  2017        PMID: 28336182     DOI: 10.1016/j.blre.2017.03.002

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  6 in total

1.  An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis.

Authors:  Alice Nevone; Maria Girelli; Silvia Mangiacavalli; Bruno Paiva; Paolo Milani; Pasquale Cascino; Maggie Piscitelli; Valentina Speranzini; Claudio Salvatore Cartia; Pietro Benvenuti; Ibai Goicoechea; Francesca Fazio; Marco Basset; Andrea Foli; Martina Nanci; Giulia Mazzini; Serena Caminito; Melania Antonietta Sesta; Simona Casarini; Paola Rognoni; Francesca Lavatelli; Maria Teresa Petrucci; Pier Paolo Olimpieri; Stefano Ricagno; Luca Arcaini; Giampaolo Merlini; Giovanni Palladini; Mario Nuvolone
Journal:  Leukemia       Date:  2022-05-24       Impact factor: 12.883

2.  [The prognostic value of baseline serum free light chain in immunoglobulin light-chain cardiac amyloidosis].

Authors:  L M Wang; T T Wang; Y Tian; L Zhao; X C Yang; W M Chen
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-01-14

3.  Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers.

Authors:  Panagiota Kyriakou; Dimitrios Mouselimis; Anastasios Tsarouchas; Angelos Rigopoulos; Constantinos Bakogiannis; Michel Noutsias; Vasileios Vassilikos
Journal:  BMC Cardiovasc Disord       Date:  2018-12-04       Impact factor: 2.298

4.  MAGE genes: Prognostic indicators in AL amyloidosis patients.

Authors:  Yang Liu; Lei Wen; Ling Ma; Ying Kang; Kai-Yan Liu; Xiao-Jun Huang; Guo-Rui Ruan; Jin Lu
Journal:  J Cell Mol Med       Date:  2019-06-20       Impact factor: 5.310

Review 5.  Amyloid Proteins and Peripheral Neuropathy.

Authors:  Mohammed M H Asiri; Sjoukje Engelsman; Niels Eijkelkamp; Jo W M Höppener
Journal:  Cells       Date:  2020-06-26       Impact factor: 6.600

6.  Prognostic Value of Circulating sST2 for the Prediction of Mortality in Patients With Cardiac Light-Chain Amyloidosis.

Authors:  Yang Zhang; Ying Xiao; Yongtai Liu; Quan Fang; Zhuang Tian; Jian Li; Daobin Zhou; Zhongpeng Xie; Ruijia Dong; Shuyang Zhang
Journal:  Front Cardiovasc Med       Date:  2021-01-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.